Boehringer Ingelheim (BI) has announced the publication of results from a Phase I/IIa clinical trial for its anti-Sema3A antibody candidate, BI 764524, used in the treatment of diabetic macular ischemia (DMI), a serious complication of diabetic retinopathy (DR) that can result in blindness. The trial successfully met its primary safety endpoints, demonstrating tolerability of the treatment. Additionally, the drug candidate showed promising signs of potential efficacy.
The investigational intravitreal injection is developed with the intention to re-vascularize ischemic areas in the central retina, offering a potential advance over existing standard-of-care treatments such as anti-VEGF therapy or invasive laser treatment, which can have limitations.- Flcube.com
